Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial

被引：0
|
作者：
Zucali, P. A. [1 ]
Simonelli, M. [1 ]
De Vincenzo, F. [1 ]
Fatuzzo, G. [1 ]
Bertossi, M. [1 ]
Perrino, M. [1 ]
Miggiano, C. [1 ]
Giordano, L. [1 ]
Bonifacio, C. [1 ]
Sposta, F. Mrakic [1 ]
Santoro, A. [1 ]
机构：
[1] Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
H18
引用
收藏
页码：78 / 78
页数：1
相关论文
共 50 条
  • [41] A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation positive non-squamous, advanced non-small-cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B
    Fukuhara, Tatsuro
    Nagashima, Hiromi
    Utsumi, Yu
    Suzuki, Aya
    Seike, Masahiro
    Miyanaga, Akihiko
    Azuma, Koichi
    Kisohara, Akira
    Kawashima, Yosuke
    Asahina, Hajime
    Tanaka, Hisashi
    Kanemaru, Ryota
    Miyauchi, Eisaku
    Furuya, Naoki
    Sato, Haruna
    Sakai, Kazuko
    Nishio, Kazuto
    Takahashi, Fumiaki
    Kobayashi, Kunihiko
    Maemondo, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Anlotinib plus carboplatin/pemetrexed in treatment-naive advanced non-squamous NSCLC: An open-label, randomized, phase II study
    Guo, R.
    Gao, W.
    Li, J.
    Liu, Y.
    Liu, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S801 - S801
  • [43] Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC
    McKeage, Mark J.
    Kotasek, Dusan
    Markman, Ben
    Hidalgo, Manuel
    Millward, Michael J.
    Jameson, Michael B.
    Harris, Dean L.
    Stagg, Robert J.
    Kapoun, Ann M.
    Xu, Lu
    Hughes, Brett G. M.
    TARGETED ONCOLOGY, 2018, 13 (01) : 89 - 98
  • [44] Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC
    Mark J. McKeage
    Dusan Kotasek
    Ben Markman
    Manuel Hidalgo
    Michael J. Millward
    Michael B. Jameson
    Dean L. Harris
    Robert J. Stagg
    Ann M. Kapoun
    Lu Xu
    Brett G. M. Hughes
    Targeted Oncology, 2018, 13 : 89 - 98
  • [45] A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer
    Tamiya, Motohiro
    Tamiya, Akihiro
    Kaneda, Hiroyasu
    Nakagawa, Kazuhiko
    Yoh, Kiyotaka
    Goto, Koichi
    Okamoto, Hiroaki
    Shimokawa, Tsuneo
    Abe, Tetsuya
    Tanaka, Hiroshi
    Daga, Haruko
    Takeda, Koji
    Hirashima, Tomonori
    Atagi, Shinji
    MEDICAL ONCOLOGY, 2016, 33 (01) : 1 - 7
  • [46] Pemetrexed in combination with cisplatin versus carboplatin as first-line therapy in patients with advanced-stage malignant pleural mesothelioma (MPM): A systematic review and meta-analysis.
    Srour, Samer Ali
    Stoner, Julie A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer
    Motohiro Tamiya
    Akihiro Tamiya
    Hiroyasu Kaneda
    Kazuhiko Nakagawa
    Kiyotaka Yoh
    Koichi Goto
    Hiroaki Okamoto
    Tsuneo Shimokawa
    Tetsuya Abe
    Hiroshi Tanaka
    Haruko Daga
    Koji Takeda
    Tomonori Hirashima
    Shinji Atagi
    Medical Oncology, 2016, 33
  • [48] A combination of pemetrexed and carboplatin as first-line treatment for advanced non-squamous non-small cell lung cancer without epidermal growth factor mutation: A multicenter, phase II trial (CJLSG0906)
    Kogure, Y.
    Kimura, T.
    Saka, H.
    Kojima, E.
    Ogasawara, T.
    Kondo, M.
    Taniguchi, H.
    Saito, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S829 - S829
  • [49] First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation
    Xiong, Yanjuan
    Wang, Lu
    Zhang, Weihong
    Meng, Yuan
    Wang, Yang
    Shen, Meng
    Zhou, Li
    Li, Runmei
    Lv, Yingge
    Wang, Shengguang
    Ren, Xiubao
    Liu, Liang
    BMC CANCER, 2024, 24 (01)
  • [50] First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)
    Mok, Tony
    Kim, Dong-Wan
    Wu, Yi-Long
    Solomon, Benjamin J.
    Nakagawa, Kazuhiko
    Mekhail, Tarek
    Felip, Enriqueta
    Cappuzzo, Federico
    Paolini, Jolanda
    Usari, Tiziana
    Tursi, Jennifer
    Blackhall, Fiona Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345